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Background: We recently developed a freely available mobile app (TB Mobile) for both iOS and Android platforms
that displays Mycobacterium tuberculosis (Mtb) active molecule structures and their targets with links to associated
data. The app was developed to make target information available to as large an audience as possible.
Results: We now report a major update of the iOS version of the app. This includes enhancements that use an
implementation of ECFP_6 fingerprints that we have made open source. Using these fingerprints, the user can
propose compounds with possible anti-TB activity, and view the compounds within a cluster landscape. Proposed
compounds can also be compared to existing target data, using a näive Bayesian scoring system to rank probable
targets. We have curated an additional 60 new compounds and their targets for Mtb and added these to the
original set of 745 compounds. We have also curated 20 further compounds (many without targets in TB Mobile) to
evaluate this version of the app with 805 compounds and associated targets.
Conclusions: TB Mobile can now manage a small collection of compounds that can be imported from external
sources, or exported by various means such as email or app-to-app inter-process communication. This means that
TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also
cluster compounds and use internal algorithms to help identify potential targets based on molecular similarity. TB
Mobile represents a valuable dataset, data-visualization aid and target prediction tool.
Keywords: Mobile app, Mycobacterium tuberculosis, TB mobile, Tuberculosis, Target predictionBackground
Efforts to make data accessible and useful for drug dis-
covery are needed perhaps now more so than ever be-
fore. Over the past decade we have seen considerable
investments in high throughput screening which adds to
the quantity of data available [1]. In particular the focus
of our work is on tuberculosis (TB) caused by Mycobac-
terium tuberculosis (Mtb). TB infects nearly 33% of the
entire world population and causes approximately 1.3
million deaths each year based on the 2013 WHO global
tuberculosis report [2-5]. Increased incidence of TB in
both developing and industrialized countries, including* Correspondence: ekinssean@yahoo.com
3Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342,
Burlingame, CA 94010, USA
4Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina,
NC 27526, USA
Full list of author information is available at the end of the article
© 2014 Clark et al.; licensee Chemistry Central
Commons Attribution License (http://creative
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the USA is of concern and exacerbated by the wide-
spread emergence of drug-resistant (multidrug-resistant
TB (MDR-TB)) strains [6] and co-infection with the hu-
man immunodeficiency virus (HIV). Even more troub-
ling is the emergence of extensively drug-resistant
(XDR) TB which is present in nearly 60 countries [7].
The pipeline for TB therapeutics is limited, [8,9], having
produced the first drug in 40 years in 2012 in the form
of bedaquiline for multidrug resistant TB [10,11]. Part of
the difficulty in drug discovery has been due to poor
success of target-based high-throughput screening [12].
In the last 10 years there has been a marked shift in
favor of high-throughput screening in whole cells
[13-18]. Unfortunately the hit rates of this approach are
usually low single-digit (or less) [1,16,19,20] which
makes this a very costly and wasteful exercise. In
addition, finding hits active in whole cells provides no
information on the likely target, which is important toLtd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a generally very slow and a further costly process.
Various efforts have been described for predicting and
prioritizing which Mtb targets to consider for drug design
that represent sophisticated workflows combining methods
such as pathway/network analysis, flux balance studies and
comparative genomics, structure assessment and binding
pocket analysis [21-24]. The addition of binding site simi-
larity and docking have also been used to propose targets in
the TB proteome for FDA approved drugs [25,26]. Follow-
ing whole cell screening, whole-genome sequencing of re-
sistant mutants and recombineering it is possible to identify
targets for compounds experimentally [27]. In contrast to
these approaches, computational prediction of compounds
and their targets (target deconvolution) has involved ligand
similarity using Bayesian methods as a domain fishing
model [28] and other methods [29]. We previously de-
scribed [30] how we initially curated >700 molecules with
Mtb target/s along with various links to the target, genes
(tbdb.org), pathways, human homolog information [31]
and essentiality data [32]. This information initially
comprised a dataset publically available in the Collab-
orative Drug Discovery (CDD) database [31]. We then
used this dataset as the basis to generate a simple mo-
bile app called TB Mobile, which is useful for viewing
and manipulating data about compounds with activity
against Mtb, their targets and other related informa-
tion [30]. We had also used the app to make predic-
tions previously [33,34] including for a set of open
access compounds from GSK [17]. This work preceded
that of another group that used chemogenomics space
search, structural space search and historical assay
space search predict the same compounds [35]. The
historical assay space search used was proprietary to
GSK so this reported approach and data is not available
to other researchers. Also it would appear this group
did not take advantage of known ligands and their tar-
gets in Mtb.
Our previous work on TB Mobile demonstrated how the
app can be a useful resource to filter by target, essentiality,
human homolog and similarity search [30]. The app also
retrieves first line drugs that are present in the database as
we have previously shown. In addition we generated predic-
tions for an additional 20 compounds for which targets
were either known or unknown [30]. This testing pointed
out limitations and suggested future versions may use
predictive machine learning models [36,37] for sug-
gesting targets and it would likely require a larger set
of molecules to build further confidence. We proposed
addition of molecules for targets not currently repre-
sented or under-represented would be important as
well as balancing the bias towards over-represented
targets. At that time we had representatives of 68 tar-
gets in TB Mobile which is clearly a small fraction ofthe over 1400 possible targets in Mtb [38], but in real-
ity it probably covers the majority of characterized tar-
gets adequately and is to our knowledge the most
extensive Mtb specific database related to small mole-
cules and their targets. However it is important to re-
member the targets of replicating cells do not overlap
with targets of nonreplicating bacteria and the number
of candidate target proteins may actually be higher
[39]. We now describe our efforts to curate new data,
provide new functionality and test the app that is now




The process of dataset curation was previously described
by us and for updating purposes we performed searches for
recent papers describing molecules and known targets in
Mtb. We manually curated molecules and data combined
with URL links to literature and TBDB [41,42] and these
were deposited in the CDD database [31].
TB mobile app software development: open source
fingerprint implementation
A number of modelling projects in recent years have
successfully made use of the extended connectivity fin-
gerprints, commonly referred to as ECFP_n or FCFP_n
(n = 2, 4 or 6). For example we have experience in
apply the FCFP_6 descriptors to modeling phenotypic
HTS data for Mtb [32,36,37,43-49]. These fingerprints
are created by enumerating a collection of substruc-
tures using breadth-first expansion from a starting
atom. The fingerprint method was originally made
available as part of the Pipeline Pilot project [50,51] and
similar methods have been made available from ChemAx-
on’s proprietary JChem [52] and RDKit [53]. The Accelrys
fingerprint methodology was published in detail [54],
but the disclosure omitted a number of trade secrets,
which means that while it is now straightforward to
implement an algorithm that generates fingerprints
that are similarly effective, it is not possible to pro-
duce results that can be directly comparable between
the two different implementations.
We have need of a drop-in replacement for the
ECFP_6 fingerprints that can be readily ported be-
tween multiple toolkits and programming languages.
We have therefore built and validated an algorithm
that follows the published reference for ECFP and
FCFP fingerprints as closely as possible, and made the
resulting code available to the public as a feature in the
Chemical Development Kit (CDK) project [55,56],
under an open source license. While this is in itself a
valuable addition to the popular Java-based toolkit, we
have taken care to implement the algorithm in a
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avoiding toolkit-specific supporting algorithms, this
has allowed us to port the ECFP_6 algorithm to other
platforms, in particular the Objective-C programming
language used for native iOS apps, with literally com-
parable results, which is a key prerequisite for the new
functionality that is available in the TB Mobile app.
In the following section, we describe the ECFP_6 im-
plementation in sufficient detail such that a skilled
programmer can precisely re-implement the algorithm.
The freely available open source implementation that
is part of the CDK can be consulted for guidance, and
used to generate validation examples, to ensure that
the results are identical. The reference [54] should
first be consulted for an instructive overview of the
methodology.
Molecule preparation
The input is assumed to be a molecule that is represented
as a connection table with the lowest common denomin-
ator feature set of an MDL Molfile, i.e. all atoms are repre-
sented as symbols from the periodic table, and all bonds
have an integral bond order. Most organic molecules can
be represented using bond orders of 1, 2 and 3, but organo-
metallic compounds can also be described with bond
orders of 0 or 4 or higher [57]. Aromatic rings must be ini-
tially represented in Kekulé form, i.e. alternating single/
double bonds.
Implicit hydrogens are optional: the molecule can have
some, all or none of its hydrogen atoms listed as individ-
ual atoms, as long as the implicit hydrogen counting
method described in the algorithm obtains the expected
answer. The same identical fingerprints will be created
regardless of whether hydrogens are implicit or explicit.
Implicit hydrogens are calculated using a conservative
formula: only elements C, N, O, P and S are eligible for
auto-calculated implicit hydrogens. The respective for-
mula for each of these cases is:
carbon H = 4 - |C| - U - B
nitrogen and phosphorus: H = 3 - C - U - B
oxygen and sulfur: H = 2 - C - U - B
where C is the formal charge, U is the number of un-
paired electrons standing in lieu of bonds, and B is the
sum of the bond orders of neighbouring atoms. Note
that for carbon, the absolute value of the charge is
used. The unpaired electron count is typically listed as
1 for radicals and 2 for carbenes (it does not include
conventional lone pairs, such as those on oxygen or
nitrogen).
Any molecules for which the conservative implicit hydro-
gen calculation formula does not provide the correct struc-
ture must either be submitted using a file format thatallows the specification of the number of virtual hydrogen
atoms, or the hydrogen atoms for this atom must be cre-
ated explicitly as individual atom nodes in order that they
be counted.
Aromaticity is calculated by enumerating rings of size 6,
and labelling only those that are capable of adopting a 6π
aromatic alternating double bond forms. This does not in-
clude lone-pair aromatics (e.g. thiophene), large rings (e.g.
porphyrins), charged 5-rings (e.g. imidazolium) or exocy-
clics (e.g. cyclic amides). Ring systems such as naphthalene
or anthracene are considered aromatic for all rings, since
all rings have a qualifying resonance form.
The algorithm proceeds as:
 enumerate all 6-membered rings (excluding those
made up of smaller rings)
 evaluate each ring to see if it has alternating
single-double bonds; for each qualifying ring,
mark the atoms and bonds are aromatic and
remove the ring from the list
 loop:
 evaluate each ring for alternating single-double
bonds, whereby any bond previously marked as
aromatic is considered as a wildcard, i.e. it may be
considered as either single or double
 repeat until no more aromatic rings can be found
Stereochemistry may be encoded in a variety of ways,
e.g. wedge bonds, chiral parity, CIP labels, as long as
the algorithm is capable of making use of this descrip-
tion to derive the correct tetrahedral conformation. 3
otherwise identical molecules with different chiral
states (i.e. R, S or unspecified) can usually be expected
to deliver 3 different sets of fingerprints, though they
will be similar (note however that in some cases the
limited reach of the circular fingerprints means that
chirality does not resolve to different atom identities,
especially for FCFP class fingerprints).
The internal representation used by this algorithm is
done by considering every p-block element with 4 sub-
stituents (one of which may be an implicit hydrogen): if
it is marked with a chiral parity flag, or has at least one
wedge bond, then an attempt will be made to map the 4
substituents onto a tetrahedron:
If the 4 substituents are mapped onto a tetrahedron
in an order that is equivalent to the above, the atom
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e.g. [A, B, C, D] where the letters correspond to an
atom index, or none in the case of an implicit hydrogen
placeholder. For this array of size 4, there are a total of
24 permutations. Each permutation has an odd or even
parity relative to the starting geometry, e.g. [B, A, C,
D] is an odd permutation (one swap) while [B, A, D, C]
is an even permutation (two swaps). Even permutations
refer to an equivalent geometry, i.e. the tetrahedron
can be rotated around to its original position, while
odd permutations are inequivalent, i.e. if the substitu-
ents are different, then it cannot be restored to its
original state by rotation, which means it is enantio-
meric. Therefore by creating an array [A, B, C, D] that
is representative of the geometry, or any even permuta-
tion of it, the necessary chirality information is
encoded. This will be used during the fingerprint gen-
eration process. This array is referred to as the tetrahe-
dral rubric for the atom. Note that it is valid to
generate this for an atom even if it is not actually
chiral: the symmetry, or lack thereof, will be resolved
during the assignment process.ECFP atom identity
For the ECFP-class of fingerprints, each non-hydrogen
atom is assigned an initial identity which is made up by
first determining the following properties:
 N = number of heavy atom neighbours
 H = number of hydrogen neighbours (implicit and
explicit)
 D = atom valence - number of hydrogens (implicit
and explicit)
 A = atomic number
 C = formal ionic charge (integer)
 R = 1 if the atom is in a ring (of any size), 0
otherwise
The initial hash code of each atom is composed by
adding the following bytes to a CRC32 calculation:
 (N < < 4) | D
 A
 C + 0x80
 (H < < 4) | R
The CRC32 calculation is the same method used by
PNG and ZIP files, and is described in: http://www.w3.
org/TR/PNG/#D-CRCAppendix. The link also provides
an implementation example in C.
An array of size equal to the number of atoms is used to
store the identity of each atom, and this is used in subse-
quent steps.As well as assigning a value to each atom for subse-
quent use, each non-hydrogen atom is recorded in a
datastructure with the following properties:
 hash code (32-bit signed integer)
 iteration (integer)
 atom list (array of integers)
For these initial atom assignments, the iteration is set
to 0, and the atom list is an array with a single value,
that being the index of the atom.
Note that duplicate hash codes are retained in the fin-
gerprint list, because for the 0th iteration, entries with
duplicate hash codes have a different atom list, which is
important for subsequent steps.
If the requested fingerprint diameter is 0 (i.e. ECFP_0),
the algorithm stops at this point.Propagation
Once the initial atom identities are established, some
number of iterations are performed. The most com-
monly used iteration count is 3, which gives rise to
the ECFP_6 and FCFP_6 fingerprints. Each iteration
generates zero-or-more additional hash codes. Tiny
molecules may not generate any new fingerprints in it-
erations 2 or 3, i.e. the results for ECFP_2 or ECFP_4
may not be any different than what would have been
obtained for ECFP_6 fingerprints.
The following process is repeated for each iteration,
i.e. 1, 2 or 3 times.
A new identity array is defined, and for each non-
hydrogen atom, a new identity value is calculated in the
following way:
An array of pairs is defined, with one entry for each
non-hydrogen neighbor. The values for each of these
pairs are defined as [bond,identity], i.e.
 literal bond order (0, 1, 2, 3, …) or 15 if the bond is
aromatic
 the identity of the neighbor atom from the previous
iteration
These pairs are then sorted literally, first number first, e.g.
 [1,1000] < [2,-500]
 [1,-500] < [1,1000]
This list of pairs is then prefixed by the current iter-
ation, and the current atom identity from the previous
iteration. For example, performing iteration 1 on an
atom with a previous identity of 200, and neighbour pairs
of [2,-500] and [1,1000] would result in a sequence of
[1,200,1,1000,2,-500].
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ing way:
As a final addendum, if the atom has a tetrahedral
rubric array associated with it, then an additional byte
may be fed into the CRC32 hashing sequence. At the
beginning of the overall fingerprint calculation process,
each atom is assigned a chirality flag that is set to
false. At each iteration, if the flag is still set to false,
and there is a rubric array, then a determination is
done: the rubric array of [A,B,C,D] is substituted for
the atom identity (from the previous iteration) for each
of its neighbours. Any neighbour that is a hydrogen
atom (explicit or explicit) is given a value of 0. If any
two values of this array are the same, then this step is
skipped.
The new array of [a,b,c,d] is examined to determine
how many swaps are necessary to order the array from
lowest to highest. If the number of swaps is even, 1 is
appended to the CRC32 sequence, otherwise 2 is
appended. The chirality flag is set for the atom, so that
it will not be further annotated in subsequent iterations.
Once the new identities are calculated for each heavy
atom, the algorithm iterates over these atoms and cre-
ates a new fingerprint proposal for each one:
 hash code (newly computed for this iteration)
 iteration number (1, 2 or 3)
 atom list
 The last parameter, atom list, is a breadth first
growth corresponding to the iteration. The initial
fingerprints that were generated at iteration 0
defined this to contain a single atom index.
Fingerprint proposals for iteration 1 contain the
starting atom and all their neighbors; for iteration 2,
the neighbors’ neighbors are included, etc. The atom
lists may be cached for efficiency purposes or
recomputed. They should also be sorted and not
contain duplicates, e.g. if atom 10 has neighbors 5, 7
and 12, the atom list for the proposed fingerprint at
iteration 1 would be [5,7,10,12].
Once the proposed fingerprint is defined, the existing
list of fingerprints is searched: if the sorted unique list ofatoms matches any of the fingerprints already in the list,
then only one of them may be retained:
 If the existing fingerprint has an earlier iteration
number, discard the new one; else
 replace the existing fingerprint if the new one has a
lower hash code.
This is done in order to reduce the degree of redun-
dancy. Once the propagation steps are complete, the
final output is the list of retained hash codes (signed 32-
bit integers), sorted, with duplicates removed. These lists
of integers are used for all of the similarity metrics de-
scribed in this work.
Similarity
TB Mobile allows the user to draw or paste a chemical
structure as a query molecule, which causes the main
compound display list to be sorted by most-to-least
similar to the provided reference structure. Version 2 of
the app has been updated to use the ECFP_6 fingerprints
described in this work. Similarity is evaluated by com-
puting the Tanimoto coefficient [58]. The calculation is
done using the raw list of unique 32-bit hash codes, ra-
ther than folding into packed bitmasks.
Clustering
The algorithm behind the visual clustering interface in
TB Mobile performs a simple 2D embedding of a collec-
tion of molecules, then dynamically repositions them
based on predefined tethers. The input parameters con-
sist of a selection of compounds, and a central reference.
For performance and display space purposes, the num-
ber of compounds is reduced by keeping the 50 most
similar compounds to the reference, as determined by
Tanimoto coefficient. The remaining compounds are
converted into a graph by ensuring that each compound
has an edge to each of the 10 most similar other com-
pounds in the remaining set. If the resulting graph has
multiple components, all components other than that
which contains the reference are discarded. Once this
process is complete, any compounds that are contained
in the user-provided collection are added to the set, and
tethered in the same way (i.e. they are always a part of
the display, and are never pruned out).
Initial placement is done in a greedy fashion: the refer-
ence compound is placed at (0,0). The tether graph is
walked in a breadth-first fashion, and for each bracket,
the candidates are ordered by their average similarity to
already placed compounds. Each is placed roughly by
sampling positions that minimize the distance to teth-
ered neighbors, but does not permit overlap, assuming
that each node has a fixed radius. Once the initial place-
ment is complete, the layout is shown to the user, and a
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optimize a scoring term that encourages closeness teth-
ered atoms vs. repulsion of non-tethered atoms. This is
conceptually analogous to a forcefield, except with arbi-
trary terms tailored to aesthetic positioning.
Target prediction
We updated TB Mobile with 60 new compounds and
data (Additional file 1: Table S1) so the app now con-
tains 805 compounds, (as of March 2014). There are 96
unique targets, for which 53 have 2 or more known
binders in the dataset. The target/compound distribu-
tion is shown in Additional file 2: Table S2. We have
evaluated the app with an additional set of 20 com-
pounds (Additional file 3: Table S3). First they were all
drawn in the Mobile Molecular DataSheet (MMDS) app
and copied into the TB Mobile app (an example of app-
to-app communication). Molecules can also be drawn
within the TB Mobile app itself. The similarity searching
component was used to rank the content in TB Mobile
of molecules with known targets (Additional file 4:
Figure S1-20). We have used this as an example of infer-
ring potential targets and compared this to the pub-
lished data for these molecules (Table 1). It should be
noted that such data is far from definitive as these pub-
lished compounds have not been tested versus all Mtb
targets and it is possible the same compound may be active
against more than one target. We generated screenshots
for the top compounds (Additional file 4: Figure S1-20) and
output the Bayesian scores into MMDS (Table 1).
In order to provide a guide for whether a proposed
compound is likely to be active against any of these tar-
gets, a simple modified Bayesian approach is used. For
each listed target with at least two binders, it is first as-
sumed that all of the molecules in the collection that do
not indicate this as one of their targets are inactive. For
each of the 805 constituent molecular structures, the
ECFP_6 fingerprints are calculated. For each molecule, a
score is determined using the Laplacian-modified naïve
Bayesian classified described by Jenkins et al., among
others [50,51,67]. The estimation score is a sum of log
values, which can be transformed into a probability or used
to classify as true or false based on a selected threshold.
The score for each molecule is calculated in a leave-
one-out fashion, i.e. its own contribution is excluded
from the list of known fingerprints and activities. The
score is a sum of log values of probabilities, with arbi-
trary upper and lower limits. For these a threshold can
be selected, above which a molecule is predicted to be
active against the target. By varying the threshold be-
tween the upper and lower bounds, it is also possible to
create a receiver-operator-characteristic (ROC) curve, by
determining the true/false positives and negatives for
each threshold. Figure 1 shows response metrics for theInhA target which has 157 compounds targeting it. We
have generated similar analyses for other targets in TB
Mobile (Additional file 5: Table S4).
The ROC curve in Figure 1a shows the response for
both the ECFP_6 fingerprints described in this work, as
well as the FCFP_6 variant. At the same time as we sub-
mitted the ECFP fingerprint capabilities to the CDK pro-
ject, we also made available the FCFP equivalent, which
is identical except that it initially describes each atom by
whether it is an H-bond donor/acceptor, positive/nega-
tive charge center, aromatic and/or halogen. For the TB
Mobile app, we use only the ECFP variant. Figure 1b
shows the Bayesian estimator scores, binned at intervals
to produce a bar chart. As can be seen, there is little over-
lap between the scores for the known binders and the
remaining compounds in the collection, with the caveat
that the small dataset is biased by a number of recurring
structural motifs, some of which are shown in Figure 1c.
When the mobile app considers a user-proposed com-
pound for possible activity against a given target, the
modified Bayesian score is calculated in the same way. If
the resulting score falls within the range of the ROC
plot, i.e. if the score were to be used as a threshold then
the confusion matrix would report at least one false
positive or false negative, then the probability of activity
is expressed as a value between 0 and 1, depending
where it falls between the lower and upper bounds. If
the score lies outside of the range of the ROC plot, it is
set to 0 or 1.
This prediction method is essentially a normalized
similarity metric, for which proposed compounds are
ranked favorably if they are similar to known target
binders. This approach compliments the sorting of mol-
ecules in TB Mobile by similarity described herein.
Interoperability
The TB Mobile app supports a number of ways of mov-
ing data into and out of the app, which is in keeping
with the mobile app interoperability features we have de-
scribed previously [68,69]. Other than providing a built-
in structure editor [70] and the ability to read structure
formats from the clipboard, the importing capability is
offered by registering the app as a receiver for a several
common structure formats, such as MDL Molfile and
SDfile. As shown in Figure 2, this can be used to con-
nect the app with content downloaded from the mobile
browser. The same mechanism applies to downloaded
email attachments, files from hosting apps such as Drop-
box, and the launching of content dynamically generated
by other apps.
Exporting content can be achieved in several ways.
From within the detail view for any given compound,
the molecular structure can be copied to the clipboard
or launched into another app. From the main menu, it is
Table 1 20 compounds used to evaluate the app and target and predictions




















Rv3791 DprE2 (0.09) Rv3790
DprE1 (0.16) Rv0005 GyrB (0.03)
Rv3423c Alr (0.56) Rv0206c
MmpL3 (0.01)
Khan C-1 ATP synthase [60] FabH Rv1885c (0.002)
Rv2150c FtsZ (0.08)
Rv2150c FtsZ (0.07)
Khan C-2 ATP synthase [60] KasB Rv2150c FtsZ (0.06)
Rv3423c Alr (0.11)
Rv2150c FtsZ (0.04) Rv3423c Alr
(0.01)
Khan C-3 ATP synthase [60] KasB Rv2150c FtsZ (0.09)
Rv3423c Alr (0.08)
Rv2150c FtsZ (0.07) Rv3423c Alr
(0.06)
Khan C-4 ATP synthase [60] InhA Rv1885c (0.25)
Rv3790 DprE1 (0.24)
Rv1885c (0.24) Rv3791 DprE2
(0.15) Rv3790 DprE1 (0.08)
Khan C-5 ATP synthase [60] KasB Rv2150c FtsZ (0.14) Rv2150c FtsZ (0.12)









Rv2150c FtsZ (0.01) Rv2155c
MurD (0.007) Rv2964 PurU
(0.007)
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PtpB Rv2150c FtsZ (0.08) Rv2150c FtsZ (0.08)
Gao
Domiphen





Rv2150c FtsZ (0.15) Rv2780 Ald
(0.35) Rv3791 DprE2 (0.008)
Rv3790 DprE1 (0.03) Rv1484
InhA (0.17) Rv3423c Alr (0.34)









Rv2150c FtsZ (0.53) Rv3791
DprE2 (0.06) Rv3790 DprE1
(0.13) Rv0005 GyrB (0.19)








Rv2150c FtsZ (0.39) Rv2780 Ald
(0.46) Rv3791 DprE2 (0.03)
Rv3790 DprE1 (0.15) Rv1484
InhA (0.009) Rv0005 GyrB (0.11)




Rv1484 InhA* [64] Kas B
(InhA 2nd
and 3rd)
No prediction Rv3791 DprE2 (0.009)
Pauli zinc
02931014
InhA Rv2150c FtsZ (0.31)
Rv2150c FtsZ (0.27), Rv2780 Ald




Rv1484 InhA* [64] InhA Rv2150c FtsZ (0.31) Rv2150c FtsZ (0.27) Rv2780 Ald











Rv1885c (0.07) Rv2155c MurD
(0.11) Rv2964 PurU (0.11)
Rv3790 DprE1 (0.03) Rv3791





Dxs1 Rv2150c FtsZ (0.4) Rv2150c FtsZ (0.3) Rv3790 DprE1
(0.05)
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Rv2150c FtsZ (0.32) Rv2155c
MurD (0.03) Rv2964 PurU (0.03)






Rv1885c Rv1885c (1), Rv3790
DprE1 (0.18)
Rv1885c (1), Rv3790 DprE1
(0.18), Rv3790 DprE1 (0.11)
Li cpd 4 Rv0548cMenB [66] Glf Rv1885c (0.26)
Rv2150c FtsZ (0.13)
Rv1885c (0.26) Rv2150c FtsZ
(0.13) Rv2780 Ald (0.06)




Rv1885c (0.22) Rv2150c FtsZ
(0.13) Rv2780 Ald (0.07) Rv2155c
MurD (0.06) Rv2964 PurU (0.06)
(*targets in TB mobile version 2.0, Targets in Bold are correctly predicted based on published data).
Clark et al. Journal of Cheminformatics 2014, 6:38 Page 9 of 17
http://www.jcheminf.com/content/6/1/38possible to initiate an outgoing email with attachments that
contain structures for all of the compounds currently being
displayed. Figure 3 shows an example where all structures
that bind the InhA target (a) are shown, and the outgoing
email (b) in progress. The datasheet attachments are in-
cluded automatically by the app. The personal collection of
compounds can also be exported by launching with other
apps, as shown in Figure 4a. If target predictions have been
made for these compounds, then they will be included as
additional fields, which can be viewed and manipulated
using other apps such as MMDS, shown in Figure 4b.Figure 1 Predictions for the InhA target: (a) the ROC curve with ECFP
active and inactive compounds; (c) structures of selected binders.The clustering feature can be used to create presenta-
tion quality graphics, as shown in Figure 5. On request,
the app will create a PDF document with a single page
representing the cluster, which is previewed onscreen.
From there it can be sent as an email attachment, or
printed directly from the app, if there is a printer config-
ured and accessible.
TB mobile app software application
We have previously described the functions and applica-
tions of the TB Mobile app in detail [30] which uses_6 and FCFP_6 fingerprints; (b) modified Bayesian estimators for
Figure 2 Importing compounds from the web: (a) setting up an SDfile download with CDD Vault; (b) selecting the TB Mobile app as
the destination; (c) molecule import on launch; (d) the personal stash, with imported structures.
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Figure 3 Sending selected compounds by email: (a) initiating the transmission for structures shown onscreen; (b) writing the email,
with prepackaged attachments.
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have updated the aesthetics and we still enable the ori-
ginal features such as scrolling through molecules and
similarity searching but now we based the similarity
comparisons on our ECFP_6 implementation. Most
similar compounds are listed first (from top left to bot-
tom right) in the app.
Results
Fingerprints comparison with published data
Several collections of TB related compounds have been
previously used for generating Bayesian Models by us.
For two TB in vitro screening datasets, with activity
expressed as true or false, a simple Bayesian model was
constructed, using a popular Laplacian-corrected variant
implemented in this study for TB Mobile [50,51,67]. The
activity for each compound was predicted using leave-
one-out. Using a grade of cutoff thresholds, an ROC plot
is created, by plotting false negatives against false posi-
tives. This enabled comparisons to the previously pub-
lished ROC values for the two datasets using FCFP_6
descriptors, noting that in these published models sev-
eral interpretable descriptors were also included. It also
enabled us to compare how ECFP_6 and FCFP_6 de-
scriptors perform for the same datasets.
We observed that for the models generated in this
study and previously published, the ROC values werecomparable (Table 2). In addition there was no appre-
ciable difference between the performance of ECFP_6
and FCFP_6 descriptors for the same datasets.
Dataset curation
An additional 60 molecules with target related information
from the literature (Additional file 1: Table S1) were curated
for use in CDD and TB Mobile. These compounds were
assessed using principal component analysis (PCA) using
Discovery Studio with the interpretable descriptors chosen
previously (AlogP, molecular weight, number of rotatable
bonds, number of rings, number of aromatic rings, number
of hydrogen bond acceptors, number of hydrogen bond do-
nors, and molecular fractional polar surface area) to assess
their overlap in chemical space (Figure 6a). The new com-
pounds appear to be within the existing chemical space of
the original dataset.
TB mobile version 2.0
As with the previously described version 1 of TB Mobile
[30] the app first organizes its data, then displays the
main screen. We will now describe and focus on the
newly added features.
Predicting targets for new compounds
We have curated an additional set of 20 compounds
(Additional file 3: Table S3) which were scored with
Figure 4 Exporting the personal collection: (a) initiating the export, the molecules in the compound collection havebar icons
representing predicted targets using the Bayesian models with extended connectivity fingerprints. The top icons (from left to right)
represent adding molecules – which can be drawn in the app, drawn with other apps on the device, pasted in from elsewhere or there is the
option to remove all structures. The second icon allows the contents of the molecule stash to be opened in other apps on the device. The third
icon allows you to email the contents of the molecule stash and the fourth icon generated target predictions.The arrow icon aligned with each
molecule allows the molecule to be either copied to the clipboard, transferred to the main window on the app or the structure can be edited or
deleted; (b) importing the datasheet into MMDS, with predictions included.
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represented in this set were in TB mobile e.g. FtsZ,
InhA, ClpC1, GyrB. Interestingly the one compound tar-
geting FtsZ was predicted based on similarity ranking in
the app to target InhA (Additional file 4: Figure S1),
while the Bayesian predictions suggested multiple targets
(Table 1). While bedaquiline is known to target ATP
synthase [10,11] it was not shown to be similar in TB
Mobile to the ATP synthase targeting compounds in the
test set (Additional file 4: Figure S2-7). The very large
macrocyclic compounds were not predicted by similarity
ranking or Bayesian approaches in the app (Additional
file 4: Figure S8-9). These compounds do however look
similar to PtpB compounds for which there are 3
examples in TB Mobile (Additional file 5: Table S4e).
The GyrB inhibitor was correctly ranked in the app
(Additional file 4: Figure S10) and was one of the
targets selected with the Bayesian model approach
(Table 1). The three InhA compounds (Additional file
4: Figure S11-13) were well predicted based on ranking
in the app with 2 out of the three being ranked as
the top targets, while one was selected also using
the Bayesian approach alongside several other targets(Table 1). A set of acetohydroxyacid synthase and
MenB inhibitors were predicted to be similar to several
targets (Additional file 4: Figure S14-S20), based on
searching TB Mobile and using Bayesian approaches
(Table 1). The comparison of Bayesian models gener-
ated with version 1 data (N = 745 molecules) and ver-
sion 2 data suggests that some targets are added with
the Bayesian approach (see Kale cpd 23, (Table 1)
for which GyrB is predicted in version 2 but not ver-
sion 1). These 20 compounds were also assessed
using PCA. Most of the compounds were within the
space of the 805 compounds although there were
several that were outside or on the edge of this
chemistry space such as the macrocyclic compounds
(Figure 6b). This evaluation set illustrates how diffi-
cult it is identify targets for new compounds. Many
contain substructures that are present in compounds
known to bind other targets. In addition limitations
of the approach are clear if the target is not repre-
sented in the dataset to begin with. This approach
also illustrates an opportunity to try to identify or
design compounds targeting multiple Mtb targets by
using features shared by several targets.
Figure 5 Exporting presentation graphics for a cluster. An example of clustering with the known targets of molecules highlighted in
different colors. This is enabled by selecting the icon on the top left and choosing the desired targets. Molecules from the collection are shown
with a white circle, molecules from the app have a grey background and compounds of interest for clustering have a blue background. The
cluster image can be expanded or contracted with a pinching motion on the screen. and molecules can be moved which causes the network
clusters to reconfigure. The cluster image can be output and printed as a PDF. (a) the interactive display; (b) previewing the PDF file, prior to
sending by email or printing.
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Our goal in creating TB Mobile [30] was to make this
potentially useful drug discovery data from CDD avail-
able in a form accessible to scientists in general and pro-
vide a novel way to predict potential targets. We have
seen in recent years a clear development in apps that
can be used in drug discovery or chemistry [71], which
suggested to us that creating a mobile app would ensure
we reached a much wider audience. This work also fol-
lows on from our efforts to make other types of science
data more readily accessible such as green solvent data
[72] and rare and neglected disease data [73]. TB Mobile
was made freely available for iOS (iPhone, iPod, iPad) in
2012 and Android devices in 2013 and has been updatedTable 2 Testing the fingerprints used in TB Mobile 2.0
Dataset
Combined model (5304 molecules) ECFP_6 fingerprints
Combined model (5304 molecules) FCFP_6 fingerprints
MLSMR dual event model (2273 molecules) and ECFP_6 fingerprints
MLSMR dual event model (2273 molecules) and FCFP_6 fingerprints
Previously published Mtb HTS datasets were used for Bayesian model building. Pub
were also included [46,47].regularly. It has been downloaded nearly 2000 times to
date and has been used by us elsewhere [33]. While
our initial apps have focused on performing one or two
functions we have proposed that apps can be used in
workflows [68,69]. With version 2 we have greatly ex-
panded TB Mobile so that not only does it provide a
look up of the molecules with known targets and other
information, we can also load a library of molecules
which can then be used for prediction. The prediction of
target-molecules is enabled using extended connectivity
fingerprints (ECFP_6) and a naïve Bayesian method and
can in turn output the data.
This report now highlights a more valuable component
of mobile app workflows to see if the compound had beenLeave one out
ROC published






lished studies used FCFP_6 descriptors and several interpretable descriptors
Figure 6 Principal component analysis. a. Using the 745 compounds in TB Mobile version 1 and the 60 additional compounds added in TB
Mobile 2. 3 Principal Components represent 88.4% of the variance. b. Using the 805 compounds in TB Mobile version 2 and the 20 additional
compounds used to evaluate it. 3 Principal Components represent 88.4% of the variance.
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cules are and their known targets which could help in lead
optimization. We also should highlight that there will be
compounds that we are unable to predict with the Bayesian
models in TB Mobile but they can be used for a similarity
searching (Table 1, Additional file 4: Figure S1-S20). This
may represent a useful way to identify compounds that
may be too dissimilar to compounds in TB Mobile. Clearly
the app was developed to suggest potential targets to assist
researchers in identifying potential targets. But it is a pre-
diction based on a relatively limited number of targets and
their known ligands and should be used with some caution.
We are not trying to predict affinity for the targets but to
narrow down the potential number of targets for experi-
mental verification.
In the process of curating data we have added an add-
itional 18 targets/mechanisms as well as a number of
additional compounds for other recent targets of interest
such as MmpL3 which should help balance the bias to-
wards targets that are over represented like InhA. We
previously suggested the need to normalize the similarity
search for the frequency of a target in the dataset which
essentially we have achieved with the Bayesian method
that builds models for the individual targets (Additional
file 5: Table S4). These efforts to collate data for individ-
ual Mtb targets may in itself be useful for drug design
purposes. The curation of the 20 molecule evaluation set
could in turn be added back into the app so that it now
includes the additional targets unique to this set.
Version 2 of TB Mobile expands on the delivery of high
quality data by adding some advanced workflow capabil-
ities, in a manner that is interactive and very accessible to
scientists who are not experts in cheminformatics. As data
regarding tuberculosis targets continues to be collated (e.g.80 molecules are included here in total), we intend to re-
lease periodic updates of the app. Presently the source data
is delivered within the app itself, and so additional data is
made available by issuing updates through the iTunes
AppStore. In the future we may further enhance TB Mobile
so that it is capable of automatically adding new data from
an online source, as it becomes available, which will ensure
that the content is current.
The proof of concept for bringing together high qual-
ity cheminformatics and bioinformatics data and easy to
use visualization on a mobile device has been carried
out for the tuberculosis domain, since it is an area of
high interest on account of the emergence of new strains
of drug resistant bacteria and its massive toll on global
public health. We can also use the app as a test case to
develop such approaches on the desktop and enhance
the CDD database. We are also actively looking into
ways to bring this mobile app workflow to other do-
mains that have a tradition of relatively nonproprietary
data access, whether that be by creating a separate app
for each subject, or looking for ways to deploy the app
more generally.
We are further investigating ways to increase the plat-
form independence of this product. Mobile devices are
popular, and building a native app is the most effective
way to provide a comprehensive and responsive user ex-
perience. The high cost of porting the product to every
major device platform is prohibitive. Our development
priority targets Apple’s iOS platform as the most import-
ant category since it has an overwhelming advantage in
the western hemisphere, but the same cannot be said for
emerging economies, which is particularly pertinent for
a disease that has the most devastating effects on trop-
ical nations. For this reason we are actively monitoring
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gies. In this case we may update the Android version
content alone and not the features for the foreseeable
future.
As we have previously used the molecules in TB Mobile
to compare to other sets of molecules to assess how they
compare to target space using PCA [44,47], the addition of
the additional compounds increases the number of targets
covered. This updated dataset will be useful for future PCA
comparisons like those described here (Figure 6a and 6b).
Now that we have an open source version of the extended
connectivity fingerprints and naïve Bayesian algorithm, we
could incorporate other predictive models in TB Mobile
such as those we have described to predict whole cell activ-
ity alongside predicting targets [32,36,37,43-47,49]. We
could also extend the concept of TB Mobile to other dis-
eases, for example diseases like malaria might be obvious
examples where there is considerable recent data on
screening that could benefit from target prediction methods
to prioritize compounds.
Additional files
Additional file 1: Table S1. The 60 compounds and targets added into
TB Mobile version 2 are in Table S1.
Additional file 2: Table S2. MtbTarget distribution in TB Mobile
Vers.2.0.
Additional file 3: Table S3. The test set of 20 compounds and their
target and pathway details are shown in Table S3.
Additional file 4: Figure S1-20. The results of the similarity searches
for compounds in Table S3 are shown in Figures S1-20. The TB Mobile
app is freely available from the Apple iTunes AppStore [40].
Additional file 5: Table S4. The Bayesian models for targets are shown
in (a-e) and shows the target prediction charts and selected binders for
targets with at least 3 examples.
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